These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 23719718

  • 1. The effects of liver impairment on the pharmacokinetics of brivanib, a dual inhibitor of fibroblast growth factor receptor and vascular endothelial growth factor receptor tyrosine kinases.
    El-Khoueiry A, Posey JA, Castillo Ferrando JR, Krishnamurthi SS, Syed S, Kollia G, Walters I, Fischer BS, Masson E.
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):53-64. PubMed ID: 23719718
    [Abstract] [Full Text] [Related]

  • 2. Lack of effect of brivanib on the pharmacokinetics of midazolam, a CYP3A4 substrate, administered intravenously and orally in healthy participants.
    Syed S, Clemens PL, Lathers D, Kollia G, Dhar A, Walters I, Masson E.
    J Clin Pharmacol; 2012 Jun; 52(6):914-21. PubMed ID: 21659627
    [Abstract] [Full Text] [Related]

  • 3. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma.
    Huynh H, Ngo VC, Fargnoli J, Ayers M, Soo KC, Koong HN, Thng CH, Ong HS, Chung A, Chow P, Pollock P, Byron S, Tran E.
    Clin Cancer Res; 2008 Oct 01; 14(19):6146-53. PubMed ID: 18829493
    [Abstract] [Full Text] [Related]

  • 4. Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate.
    Marathe PH, Kamath AV, Zhang Y, D'Arienzo C, Bhide R, Fargnoli J.
    Cancer Chemother Pharmacol; 2009 Dec 01; 65(1):55-66. PubMed ID: 19396600
    [Abstract] [Full Text] [Related]

  • 5. Lack of food effect on single-dose pharmacokinetics of brivanib, and safety and efficacy following multiple doses in subjects with advanced or metastatic solid tumors.
    LoRusso P, Shapiro GI, Hurwitz H, Pilat MJ, Chemidlin J, Kollia G, Syed S, Fischer B, Masson E.
    Cancer Chemother Pharmacol; 2011 Dec 01; 68(6):1377-85. PubMed ID: 21461891
    [Abstract] [Full Text] [Related]

  • 6. Beneficial effects of dual vascular endothelial growth factor receptor/fibroblast growth factor receptor inhibitor brivanib alaninate in cirrhotic portal hypertensive rats.
    Lin HC, Huang YT, Yang YY, Lee PC, Hwang LH, Lee WP, Kuo YJ, Lee KC, Hsieh YC, Liu RS.
    J Gastroenterol Hepatol; 2014 May 01; 29(5):1073-82. PubMed ID: 24325631
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Metabolic chiral inversion of brivanib and its relevance to safety and pharmacology.
    Gong J, Gan J, Masson E, Syed S, Xia YQ, Williams D, Pursley J, Jemal M, Humphreys WG, Iyer RA.
    Drug Metab Dispos; 2012 Dec 01; 40(12):2374-80. PubMed ID: 22983304
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Metabolism and disposition of [14C]brivanib alaninate after oral administration to rats, monkeys, and humans.
    Gong J, Gan J, Caceres-Cortes J, Christopher LJ, Arora V, Masson E, Williams D, Pursley J, Allentoff A, Lago M, Tran SB, Iyer RA.
    Drug Metab Dispos; 2011 May 01; 39(5):891-903. PubMed ID: 21289073
    [Abstract] [Full Text] [Related]

  • 12. A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors.
    Jonker DJ, Rosen LS, Sawyer MB, de Braud F, Wilding G, Sweeney CJ, Jayson GC, McArthur GA, Rustin G, Goss G, Kantor J, Velasquez L, Syed S, Mokliatchouk O, Feltquate DM, Kollia G, Nuyten DSA, Galbraith S.
    Ann Oncol; 2011 Jun 01; 22(6):1413-1419. PubMed ID: 21131369
    [Abstract] [Full Text] [Related]

  • 13. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.
    Llovet JM, Decaens T, Raoul JL, Boucher E, Kudo M, Chang C, Kang YK, Assenat E, Lim HY, Boige V, Mathurin P, Fartoux L, Lin DY, Bruix J, Poon RT, Sherman M, Blanc JF, Finn RS, Tak WY, Chao Y, Ezzeddine R, Liu D, Walters I, Park JW.
    J Clin Oncol; 2013 Oct 01; 31(28):3509-16. PubMed ID: 23980090
    [Abstract] [Full Text] [Related]

  • 14. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study.
    Johnson PJ, Qin S, Park JW, Poon RT, Raoul JL, Philip PA, Hsu CH, Hu TH, Heo J, Xu J, Lu L, Chao Y, Boucher E, Han KH, Paik SW, Robles-Aviña J, Kudo M, Yan L, Sobhonslidsuk A, Komov D, Decaens T, Tak WY, Jeng LB, Liu D, Ezzeddine R, Walters I, Cheng AL.
    J Clin Oncol; 2013 Oct 01; 31(28):3517-24. PubMed ID: 23980084
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Future treatment option for hepatocellular carcinoma: a focus on brivanib.
    Kudo M.
    Dig Dis; 2011 Oct 01; 29(3):316-20. PubMed ID: 21829023
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.